Stock Scorecard

Stock Summary for Medicinova Inc (MNOV) - $1.49 as of 5/8/2025 8:43:45 PM EST

Total Score

9 out of 30

Safety Score

12 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MNOV

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MNOV

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MNOV

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MNOV

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MNOV (12 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 0
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MNOV

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - MediciNova ( NASDAQ:MNOV ) 4/14/2025 11:00:00 PM
MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 4/14/2025 11:00:00 PM
First Patient Enrolled in NIH-Funded Expanded Access Program ( EAP ) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis ( ALS ) Patients 4/8/2025 11:00:00 PM
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 ( ibudilast ) in ALS ( COMBAT-ALS Clinical Trial ) at the 35th International Symposium on ALS/MND 12/5/2024 11:00:00 PM
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Autodesk ( NASDAQ:ADSK ) , MediciNova ( NASDAQ:MNOV ) 12/2/2024 1:56:00 PM
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - MediciNova ( NASDAQ:MNOV ) 11/14/2024 11:00:00 PM
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver 11/14/2024 11:00:00 PM
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis 11/11/2024 11:00:00 PM
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 ( ibudilast ) in ALS patients ( COMBAT-ALS ) at the 2024 Annual NEALS Meeting ( Northeast Amyotrophic Lateral Sclerosis Consortium ) 10/23/2024 11:00:00 PM
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 ( ibudilast ) in Amyotrophic Lateral Sclerosis ( ALS ) 9/30/2024 1:00:00 PM

Financial Details for MNOV

Company Overview
Ticker MNOV
Company Name Medicinova Inc
Country USA
Description MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapies for the treatment of serious diseases with unmet medical needs in the United States. The company is headquartered in La Jolla, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 1.49
Price 4 Years Ago 2.68
Last Day Price Updated 5/8/2025 8:43:45 PM EST
Last Day Volume 2,417
Average Daily Volume 12,743
52-Week High 2.55
52-Week Low 1.12
Last Price to 52 Week Low 33.04%

Valuation Measures
Trailing PE N/A
Industry PE 30.37
Sector PE 45.26
5-Year Average PE -10.97
Free Cash Flow Ratio 1.82
Industry Free Cash Flow Ratio 18.71
Sector Free Cash Flow Ratio 29.93
Current Ratio Most Recent Quarter 13.88
Total Cash Per Share 0.82
Book Value Per Share Most Recent Quarter 1.07
Price to Book Ratio 1.41
Industry Price to Book Ratio 7.62
Sector Price to Book Ratio 21.41
Price to Sales Ratio Twelve Trailing Months 82.89
Industry Price to Sales Ratio Twelve Trailing Months 89.49
Sector Price to Sales Ratio Twelve Trailing Months 25.24
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 49,046,200
Market Capitalization 73,078,838
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 1.77%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -28.91%
Reported EPS 12 Trailing Months -0.23
Reported EPS Past Year -0.23
Reported EPS Prior Year -0.18
Net Income Twelve Trailing Months -2,860,376,370
Net Income Past Year -11,049,549
Net Income Prior Year -8,571,516
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 40,359,738
Total Cash Past Year 40,359,738
Total Cash Prior Year 50,999,442
Net Cash Position Most Recent Quarter 40,359,738
Net Cash Position Past Year 40,359,738
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 52,503,551
Total Stockholder Equity Prior Year 62,378,424
Total Stockholder Equity Most Recent Quarter 52,503,551

Free Cash Flow
Free Cash Flow Twelve Trailing Months -10,643,863
Free Cash Flow Per Share Twelve Trailing Months -0.22
Free Cash Flow Past Year -10,643,859
Free Cash Flow Prior Year -7,452,337

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.01
MACD Signal -0.02
20-Day Bollinger Lower Band 1.20
20-Day Bollinger Middle Band 1.73
20-Day Bollinger Upper Band 2.26
Beta 0.46
RSI 54.43
50-Day SMA 1.67
150-Day SMA 1.92
200-Day SMA 2.21

System
Modified 5/8/2025 5:11:46 AM EST